Delving into the Latest Updates on Crucell Holland B.V. with Synapse

Overview

BACKGROUNDRecombinant adenoviruses are employed to deliver a therapeutic transgene in the liver, muscle or tumour tissue. However, to rationalise this delivery approach, the factors of variation between individuals need to be identified. It is assumed that differences between inbred strains of laboratory animals are considered to reflect differences between patients. Previously we showed that transgene expression in the liver of different rat strains was dependent on the transcription efficiency of the transgene. In the present paper we investigated if transfection of muscle and tumour tissue were also subject to such variations.METHODSVariation, in transgene expression, after intramuscular gene delivery was determined in different rodent strains and gene expression in tumours was investigated in different human and rodent cell lines as well as in subcutaneously implanted rodent tumours. The molecular mechanisms involved in transgene expression were dissected using an adenovirus encoding luciferase. The luciferase activity, the viral DNA copies and the luciferase transcripts were assessed in cultured cells as well as in the tissues.RESULTSLarge differences of luciferase activity, up to 2 logs, were observed between different rodent strains after intramuscular injection of Ad Luciferase. This inter-strain variation of transgene expression was due to a difference in transcription efficiency. The transgene expression level in tumour cell lines of different tissue origin could be explained largely by the difference of infectibility to the adenovirus. In contrast, the main step responsible for luciferase activity variation, between six human breast cancer cell lines with similar phenotype, was at the transcriptional level.CONCLUSIONDifference in transcriptional efficiency in muscles as observed between different inbred strains and between human breast cancer cell lines may be expected to occur between individual patients. This might have important consequences for clinical gene therapy. The variation between tumour types and tissues within a species are mainly at the levels of infectivity.

100 Deals associated with Crucell Holland B.V.

Login to view more data

100 Translational Medicine associated with Crucell Holland B.V.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

10

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Monoclonal antibody against influenza A viruses(AIMM Therapeutics BV) ( hemagglutinin )	Influenza A virus infection More	Discontinued
Influenza virus vaccine liposomal (Crucell)	Influenza, Human More	Pending
gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV)	-	Pending
JNJ-61187191	Respiratory Syncytial Virus Infections More	Pending
Foravirumab ( RABV-G )	Rabies More	Pending